# V12.2-PC1.9 — Structural Conformance Phase 7

## Objective

Continue Track-B conformance against the 467-row Clinical Data Ownership & Input Register without another broad UX redesign. PC1.9 targets role ownership, investigation/result provenance, MDT final authority, response confirmation, post-operative adjuvant routing and minimum-necessary information visibility.

## Implemented in this phase

### Intake / role model
- Added a distinct authenticated **Intake Nurse** role and working surface while retaining Nurse Navigator.
- Intake measurements remain explicit-unit inputs; BMI/BSA remain server-derived.
- Front Desk remains unable to write nursing intake.

### Investigation and laboratory result structure
- Diagnostic orders use the governed synthetic diagnostic catalogue, structured indication/priority/requested date and mandatory decision reason.
- Final laboratory results retain provenance, governed abnormal flags and amendment linkage.
- Reference ranges are now **read-only server-owned assay/LIS-master data** in the prototype; client range overrides are discarded. The production authority still needs to be the actual CCA LIS/assay source.

### MDT
- Coordinator records attendance and submits the recommendation.
- Quorum is derived in the product-test configuration.
- A distinct **MDT Chair** alone can Approve or Return for revision with mandatory reason and timestamp.
- Resubmission invalidates the prior Chair signature.
- Treatment Plan creation is blocked until current Chair approval.

### Response assessment
- Lesion measurement and units are recorded first; the system can derive quantitative values/propose a category.
- **Medical Oncology separately confirms** the final response category with reason/signature.
- A confirmed assessment is not silently edited.

### Surgery → adjuvant review
- Signed Operative Record + final pathology + separate pathological-stage record derive `Ready for adjuvant review`.
- MDT Coordinator and Medical Oncology tasks are created.
- MDT Chair / Coordinator, Medical Oncology and Radiation Oncology can consume the review state.
- The register still lists Pathology and inpatient team as consumers; that should be clinically confirmed rather than broadening access mechanically.

### Consent privacy
- Front Desk sees only operational consent type/status/validity/completion.
- Signer, education, language and detailed clinical consent content remain hidden from that role.

## Fresh validation

- 38 / 38 defect-remediation checks PASS
- 48 / 48 process + IPD checks PASS
- 95 / 95 regression checks PASS
- 41 / 41 synthetic scenarios PASS
- scenario preflight failures: 0
- scenario audit errors: 0
- 15 / 15 PC1 pre-clinician checks PASS
- 9 / 9 PC1.1 UX checks PASS
- 19 / 19 PC1.2 Mature Oncology UX checks PASS
- 27 / 27 PC1.3 Track-B Phase-1 checks PASS
- 38 / 38 PC1.4 Track-B Phase-2 checks PASS
- 58 / 58 PC1.5 Track-B Phase-3 checks PASS
- **57 / 57 PC1.9 Track-B Phase-7 checks PASS**
- Python compile PASS
- all included frontend JavaScript syntax checks PASS
- clean synthetic demo reset completed after validation

## Lineage caveat

The standalone PC1.6, PC1.7 and PC1.8 acceptance scripts were not present in the active local runtime. They were therefore **not** represented as freshly rerun. PC1.9 was reconstructed from the full local PC1.5 package plus documented later structural deltas/evidence, and the Phase-7 acceptance suite explicitly re-tests the important reconstructed behaviors.

## Track-B interpretation

The Phase-7 register contains evidence on 231 / 467 rows, with 22 currently at full `CONFORMS`. Rows without all six conformance dimensions remain NOT TESTED/blank. This is deliberate evidence discipline, not a failure count.

The release still uses synthetic content and is not a production/clinical/regulatory readiness claim.
